G Costagliola1, M Cosci O di Coscio1, B Masini1, F Baldinotti2, M A Caligo2, N Tyutyusheva1, M R Sessa3, D Peroni1, S Bertelloni4. 1. Division of Paediatrics, Department of Clinical and Experimental Medicine, Pediatric and Adolescent Endocrinology, University of Pisa, Pisa, Italy. 2. Laboratory of Molecular Genetics, Azienda Ospedaliero Universitaria Pisa, Pisa, Italy. 3. Laboratory of Endocrinology, Azienda Ospedaliero Universitaria Pisa, Pisa, Italy. 4. Division of Paediatrics, Department of Clinical and Experimental Medicine, Pediatric and Adolescent Endocrinology, University of Pisa, Pisa, Italy. s.bertelloni@ao-pisa.toscana.it.
Abstract
PURPOSE: 46, XY disorders (or differences) of sex development (DSD) are a group of clinical conditions with variable genetic background; correct diagnosis is often difficult, but it permits to optimize the management. The aim of this study is to identify clinical and genetics features of a group of women with 46, XY DSD to define some issues characterizing people with 46, XY DSD in Italy. METHODS: Retrospective analysis of girls and women with 46, XY DSD and female phenotype evaluated between year 2000 and 2016, performed by anonymised database, focusing on the clinical features and management, including presentation, first diagnostic suspect, gonadal surgery and molecular diagnostic delay. RESULTS: A total of 84 records were collected (mean age at clinical presentation: 9.1 ± 7.9 years; mean age at definitive diagnosis: 20.1 ± 15.0 years). Complete androgen insensitivity syndrome was the most common diagnosis (60%). Only 12 patients (14.3%) did not receive a molecular diagnosis. Early misdiagnoses frequently occurred; diagnostic delay was 10.2 ± 11.2 years, being reduced in patients presenting from 2007 to 2016. The discordance between genotypic and phenotypic sex during pregnancy or at birth determined early reason for referral in a considerable percentage (4.9%). CONCLUSION: Misdiagnosis and long diagnostic delays are present in females with 46, XY DSD in Italy, but the new genetic techniques permit faster right diagnoses in the last years. The centralization in dedicated third level units permits to reduce the number of patients without a molecular diagnosis, allowing better clinical management and appropriate genetic counselling.
PURPOSE: 46, XY disorders (or differences) of sex development (DSD) are a group of clinical conditions with variable genetic background; correct diagnosis is often difficult, but it permits to optimize the management. The aim of this study is to identify clinical and genetics features of a group of women with 46, XY DSD to define some issues characterizing people with 46, XY DSD in Italy. METHODS: Retrospective analysis of girls and women with 46, XY DSD and female phenotype evaluated between year 2000 and 2016, performed by anonymised database, focusing on the clinical features and management, including presentation, first diagnostic suspect, gonadal surgery and molecular diagnostic delay. RESULTS: A total of 84 records were collected (mean age at clinical presentation: 9.1 ± 7.9 years; mean age at definitive diagnosis: 20.1 ± 15.0 years). Complete androgen insensitivity syndrome was the most common diagnosis (60%). Only 12 patients (14.3%) did not receive a molecular diagnosis. Early misdiagnoses frequently occurred; diagnostic delay was 10.2 ± 11.2 years, being reduced in patients presenting from 2007 to 2016. The discordance between genotypic and phenotypic sex during pregnancy or at birth determined early reason for referral in a considerable percentage (4.9%). CONCLUSION: Misdiagnosis and long diagnostic delays are present in females with 46, XY DSD in Italy, but the new genetic techniques permit faster right diagnoses in the last years. The centralization in dedicated third level units permits to reduce the number of patients without a molecular diagnosis, allowing better clinical management and appropriate genetic counselling.
Entities:
Keywords:
Complete androgen insensitivity syndrome; Disorders of sexual development; Gonadal dysgenesis; Sex determination; Sex differentiation
Authors: G Ocal; M Berberoğlu; Z Siklar; P Bilir; R Uslu; A Yağmurlu; A Tükün; N Akar; T Soygür; S Gültan; V Tonyukuk Gedik Journal: J Pediatr Endocrinol Metab Date: 2010-11 Impact factor: 1.634
Authors: G H Sinnecker; O Hiort; L Dibbelt; N Albers; H G Dörr; H Hauss; U Heinrich; M Hemminghaus; W Hoepffner; M Holder; D Schnabel; K Kruse Journal: Am J Med Genet Date: 1996-05-03
Authors: Georgette Beatriz De Paula; Beatriz Amstalden Barros; Stela Carpini; Bruna Jordan Tincani; Tais Nitsch Mazzola; Mara Sanches Guaragna; Cristiane Santos da Cruz Piveta; Laurione Candido de Oliveira; Juliana Gabriel Ribeiro Andrade; Guilherme Guaragna-Filho; Pedro Perez Barbieri; Nathalia Montibeler Ferreira; Marcio Lopes Miranda; Ezequiel Moreira Gonçalves; Andre Moreno Morcillo; Nilma Lucia Viguetti-Campos; Sofia Helena Valente Lemos-Marini; Roberto Benedito de Paiva Silva; Antonia Paula Marques-de-Faria; Maricilda Palandi De Mello; Andrea Trevas Maciel-Guerra; Gil Guerra-Junior Journal: Int J Endocrinol Date: 2016-11-28 Impact factor: 3.257
Authors: Ute Thyen; Till Ittermann; Steffen Flessa; Holger Muehlan; Wiebke Birnbaum; Marion Rapp; Louise Marshall; Maria Szarras-Capnik; Claire Bouvattier; Baudewijntje P C Kreukels; Anna Nordenstroem; Robert Roehle; Birgit Koehler Journal: BMC Health Serv Res Date: 2018-07-05 Impact factor: 2.655